Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Clinical trials sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., explained in plain language.
-
New hope for COPD patients: drug aims to cut severe breathing attacks
Disease control OngoingThis study tests an experimental drug called TQC2938 in 256 adults with moderate to severe COPD. The goal is to see if it can reduce the number of serious breathing flare-ups over 24 weeks compared to a placebo. Participants will be randomly assigned to receive either the drug or…
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
New clotting factor shows promise for hemophilia a bleeding control
Disease control OngoingThis phase 3 trial tests a lab-made clotting factor (factor VIII) in 60 people with severe hemophilia A. The goal is to see if it safely stops bleeding when needed and works well during surgeries. Participants receive the drug on demand for new bleeds or before surgery.
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC